Publications

FT576

2022 ASH Poster Presentation

Interim Phase I Clinical Data of FT576 as Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myelomoa

2020 ASH Poster Presentation

FT576: Multi specific Off the Shelf CAR NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self Fratricide and Optimized mAb Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma
FT819

2022 ASH Poster Presentation

Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies

2021 ASH Abstract

Clinical Manufacture of FT819: Use of a Clonal Multiplexed-Engineered Master Induced Pluripotent Stem Cell Line to Mass Produce Off-the-Shelf CAR T-Cell Therapy

2019 ASH Abstract

FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical Trial

Nature Medicine. 2019; 25: 82–88.

Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency
iPSC Product Platform

2022 ASH Poster Presentation

High-Density Cryopreservation of Off-the-Shelf CAR Cells Facilitates On-demand Treatment Access
Alloimmune Defense Receptor Redirects Host Immune Cell Alloreactivity to Potentiate Functional Persistence and Anti-Tumor Activity of Off-the-Shelf Cell-Based Cancer Therapy
A CD3 Fusion Receptor (CD3-FR) Uniquely Enables Compatibility of Allogeneic CAR-T and -NK cells with T Cell Engagers to Enhance Antitumor Function and Limit Antigen Escape
Off-the-Shelf CAR-NK cell Therapy co-Targeting GPRC5D and CD38 for the Treatment of Multiple Myeloma
CD82 Is Sufficient to Uniquely Identify Pluripotent Stem Cell-Derived Hemogenic Endothelium With the Hematopoietic Lineage Potency to Give Rise To Bona Fide Lymphocytes
iPSC-derived CD38-null NK Cells in Combination with CD38-targeted Antibody: a Dual Therapeutic Strategy to Enable ADCC and Eliminate Host Immune Cells in Multiple Myeloma
Combined Genetic Ablation of CD54 and CD58 in CAR Engineered Cytotoxic Lymphocytes Effectively Averts Allogeneic Immune Cell Rejection
Characterization of Engineered Macrophages and other Myeloid Cells Differentiated from CD34+ Hematopoietic Progenitor Cells Derived from Pluripotent Stem Cells
A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogeneous Population Associated with AML
Multi-Antigen Targeting by Novel Combination of CAR-T Cells and hnCD16 Transgene Yields in Complete Tumor Clearance via Antibody Dependent Cellular Cytotoxicity
The Development of Allogeneic Tips-Derived TCR- CAR+ CD8⍺β T Cells

2022 SITC Poster Presentation

iPSC-derived NK cells Engineered with a Novel TGFβ signal Redirector Receptor Exhibit Enhanced Performance Against Solid Tumors
Trimodal CAR+TCR+hnCD16+ iPSC-derived T Cells Co-Targeting Surface and Intracellular/Neoantigens Demonstrate Additive Effect on Overcoming Tumor Heterogeneity and Cancer Escape
Novel Immune Reconstitution Model Highlights the Importance of Stealth Strategies that Potentiate Effector Cell Function and Promote Functional Persistence of Next-Generation Adoptive Cell Therapies
Off-the-Shelf iPSC-derived CAR-T cells Targeting KLK2 Demonstrate Prolonged Tumor Control and Survival in Xenograft Models of Prostate Cancer
Off-the-Shelf iPSC-derived CAR-T cells Containing Seven Functional Edits Overcome Antigen Heterogeneity, Improve Trafficking, and Withstand Immunosuppression Associated with Failed Tumor Treatment
Engineering of Synthetic Chemokine Receptors into iPSC-derived CAR-T cells to Increase Homing and Enhance Trafficking into Solid Tumors
Preclinical in vivo Model Development: Highlighting Success and Discussing Xenograft Advancements, a Step Closer in Predicting Patient Outcomes

2022 AACR Posters

A novel synthetic stealth receptor that redirects host immune cell alloreactivity and potentiates functional persistence of adoptively transferred off-the-shelf cell-based cancer therapy
Chimeric CD3 Fusion Receptors Expressed on iPSC-derived Universal TCR-less CAR-T and -NK Cells Synergize with Bispecific Engagers to Enhance Antitumor Activity and Limit Antigen Escape
Novel Combination of iPSC-derived Dual Dual -CAR NK Cells with CD16 Fc Receptor for Multi-antigen Targeting of Multiple Myeloma to Overcome Clonal Resistance and Antigen Escape
Multiplexed-engineered, iPSC-derived T Cells Expressing Three Unique Targeting Modalities Address Tumor Heterogeneity and Antigen Escape
Detection of Genetically Engineered iPSC-derived Natural Killer Cells in Blood and Tissue

2022 ASGCT Posters

Long-term Stability Assessment of Cryopreserved iPSC-derived T and NK Cells Supports Mass Production and Off-the-shelf Therapeutic Applications
Long-term Stability of iPSC-Derived CD34+ Cell Banks Supports the Sustainable Manufacture of Off-the-shelf Immunotherapies
Development of Next-Generation, Off-the-Shelf CAR T-cell Immunotherapies for Solid Tumors
Development of Master Multiplexed-Engineered iPSC Bank for Off-the-Shelf Cell-Based Cancer Immunotherapy with Reduced Conditioning Chemotherapy
10-year Stability Assessment of Cryopreserved, Engineered iPSC Banks: Genetic and Phenotypic Characterization
Robust T-cell Cellular Reprogramming and Single-cell Engineering Platform Overcomes Inconsistencies and Heterogeneity Associated with Engineering Primary T cells
iPSC-derived CD38-null NK cells in Combination with CD38-targeted Antibody Represent a Novel Therapeutic Strategy to Reduce the Requirement of Conditioning Chemotherapy for Off-the-Shelf Cell-based Cancer Immunotherapy

2021 SITC Abstract

Synthetic redirection of TGFβ receptors as a novel strategy to enhance the anti-tumor activity of CAR-T cells in solid tumors
Novel FcyR recombinant fusion facilitates antibody arming of engineered iPSC-derived NK cells to enhance targeting and killing of ovarian cancer cells
Chemokine receptor engineering enhances trafficking and homing of primary and iPSC-derived CAR-T cells to solid tumors

2021 ASH Abstract

Dual Chimeric Antigen Receptor Approach Combining Novel Tumor Targeting Strategies Circumvents Antigen Escape in Multiple Myeloma
Off-the-Shelf, iPSC-Derived CAR-NK Cells Multiplexed-Engineered for the Avoidance of Allogeneic Host Immune Cell Rejection
Combination of Three Unique Anti-Tumor Modalities Engineered into iPSC-Derived T Cells Demonstrate a Synergistic Effect in Overcoming Tumor Heterogeneity and Cancer Escape
Arming of iPSC-Derived NK Cells Expressing a Novel CD64 Fusion Receptor with Therapeutic Antibodies Represents a Novel Off-the-Shelf, Antigen-Targeting Strategy for Cancer

Stem Cell Report

Platform for Induction and Maintenance of Transgene-free hiPSCs Resembling Ground State Pluripotent Stem Cells
MENU